DAB2 and neoplasm: In contrast, another study found that Dab2 dose not impact the canonical TGF-beta pathway but Dab2 loss in head and neck cancer compromised the tumor suppressor function of TGF-beta, while enabling its tumor-promoting activities, and concluded that Dab2 is a molecular switch for TGF-beta from a tumor suppressor to a promoter (Hannigan et al., 2010).